Your browser doesn't support javascript.
loading
Potential of natural products in combination with arsenic trioxide: Investigating cardioprotective effects and mechanisms.
Wang, Jie; Liu, Yong-Mei; Hu, Jun; Chen, Cong.
Afiliação
  • Wang J; Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, Beijing 100053, China.
  • Liu YM; Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, Beijing 100053, China.
  • Hu J; Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, Beijing 100053, China. Electronic address: 1398046131@qq.com.
  • Chen C; Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, Beijing 100053, China. Electronic address: 706427081@qq.com.
Biomed Pharmacother ; 162: 114464, 2023 Jun.
Article em En | MEDLINE | ID: mdl-37060657
ABSTRACT
Over the past few decades, clinical trials conducted worldwide have demonstrated the efficacy of arsenic trioxide (ATO) in the treatment of relapsed acute promyelocytic leukemia (APL). Currently, ATO has become the frontline treatments for patients with APL. However, its therapeutic applicability is severely constrained by ATO-induced cardiac side effects. Any cardioprotective agents that can ameliorate the cardiac side effects and allow exploiting the full therapeutic potential of ATO, undoubtedly gain significant attention. The knowledge and use of natural products for evidence-based therapy have grown rapidly in recent years. Here we discussed the potential mechanism of ATO-induced cardiac side effects and reviewed the studies on cardiac side effects as well as the research history of ATO in the treatment of APL. Then, We summarized the protective effects and underlying mechanisms of natural products in the treatment of ATO-induced cardiac side effects. Based on the efficacy and safety of the natural product, it has a promising future in the development of cardioprotective agents against ATO-induced cardiac side effects.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Arsenicais / Produtos Biológicos / Leucemia Promielocítica Aguda / Antineoplásicos Limite: Humans Idioma: En Revista: Biomed Pharmacother Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Arsenicais / Produtos Biológicos / Leucemia Promielocítica Aguda / Antineoplásicos Limite: Humans Idioma: En Revista: Biomed Pharmacother Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China